LGVN official logo LGVN
LGVN 1-star rating from Upturn Advisory
Longeveron LLC (LGVN) company logo

Longeveron LLC (LGVN)

Longeveron LLC (LGVN) 1-star rating from Upturn Advisory
$0.62
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/05/2025: LGVN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.86

1 Year Target Price $6.86

Analysts Price Target For last 52 week
$6.86 Target price
52w Low $0.59
Current$0.62
52w High $2.24

Analysis of Past Performance

Type Stock
Historic Profit -92.83%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/05/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.72M USD
Price to earnings Ratio -
1Y Target Price 6.86
Price to earnings Ratio -
1Y Target Price 6.86
Volume (30-day avg) 3
Beta 0.15
52 Weeks Range 0.59 - 2.24
Updated Date 11/13/2025
52 Weeks Range 0.59 - 2.24
Updated Date 11/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.98

Earnings Date

Report Date 2025-11-12
When After Market
Estimate -0.26
Actual -0.39

Profitability

Profit Margin -
Operating Margin (TTM) -5335.77%

Management Effectiveness

Return on Assets (TTM) -60.95%
Return on Equity (TTM) -119.92%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5308845
Price to Sales(TTM) 9.13
Enterprise Value 5308845
Price to Sales(TTM) 9.13
Enterprise Value to Revenue 3.69
Enterprise Value to EBITDA -49.61
Shares Outstanding 19848876
Shares Floating 16022274
Shares Outstanding 19848876
Shares Floating 16022274
Percent Insiders 15.06
Percent Institutions 8.71

Icon representing Upturn AI-generated SWOT analysis summary Upturn AI SWOT

Longeveron LLC

Longeveron LLC(LGVN) company logo displayed in Upturn AI summary

Company Overview

Company history and background logo History and Background

Longeveron LLC is a clinical-stage biotechnology company founded in 2010. It focuses on developing cellular therapies for aging-related and life-threatening conditions. The company went public in 2021.

Company business area logo Core Business Areas

  • Cellular Therapies: Development and commercialization of Lomecel-B, a cell-based therapy derived from human bone marrow mesenchymal stem cells (MSCs), for various indications including aging frailty, Alzheimer's disease, and metabolic syndrome.

leadership logo Leadership and Structure

Longeveron's leadership team includes key executives in research, development, and commercial operations. The organizational structure is typical of a biotechnology company, with departments focused on research, clinical trials, manufacturing, and business development.

Top Products and Market Share

Product Key Offerings logo Key Offerings

  • Lomecel-B: Lomecel-B is Longeveron's primary product candidate. It is being investigated for various indications. Market share data is not yet applicable as the product is still in clinical trials. Competitors include companies developing similar cell-based therapies, such as Mesoblast (MESO), and those developing treatments for the specific indications being targeted by Lomecel-B (e.g., Alzheimer's treatments from Biogen (BIIB) and Eli Lilly (LLY)).

Market Dynamics

industry overview logo Industry Overview

The cell therapy industry is a rapidly growing field with significant potential for treating a wide range of diseases. It is characterized by high research and development costs, complex regulatory pathways, and increasing investment from both public and private sources.

Positioning

Longeveron is positioned as a leading developer of allogeneic MSC-based therapies, with a focus on aging-related conditions. Its competitive advantage lies in its proprietary cell processing technology and clinical data supporting the safety and efficacy of Lomecel-B.

Total Addressable Market (TAM)

The total addressable market for Longeveron's target indications is substantial, potentially reaching billions of dollars across aging frailty, Alzheimer's disease, and metabolic syndrome. Longeveron's positioning is focused on being a key player in the cell therapy segment.

Upturn SWOT Analysis

Strengths

  • Proprietary cell processing technology
  • Strong intellectual property portfolio
  • Experienced management team
  • Positive clinical data for Lomecel-B in certain indications

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Product is still in clinical development and not yet approved for commercial sale
  • Reliance on a single product candidate

Opportunities

  • Potential to expand Lomecel-B to other indications
  • Partnerships with larger pharmaceutical companies
  • Growing demand for cell-based therapies
  • Favorable regulatory environment for regenerative medicine

Threats

  • Competition from other cell therapy companies
  • Regulatory hurdles
  • Clinical trial failures
  • Manufacturing challenges

Competitors and Market Share

Key competitor logo Key Competitors

  • MESO

Competitive Landscape

Longeveron faces competition from other cell therapy companies, as well as companies developing treatments for its target indications. Its competitive advantage lies in its proprietary cell processing technology and its focus on aging-related conditions.

Growth Trajectory and Initiatives

Historical Growth: Longeveron's historical growth has been driven by its progress in clinical development and its ability to secure funding.

Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential commercialization of Lomecel-B. Analyst estimates vary widely depending on the perceived probability of success.

Recent Initiatives: Recent initiatives include the advancement of Lomecel-B in clinical trials for Alzheimer's disease and aging frailty, as well as exploring potential partnerships with other companies.

Summary

Longeveron is a clinical-stage biotech company focused on cellular therapies for aging-related conditions. It has a promising lead product in Lomecel-B but faces significant financial and regulatory hurdles. Its success depends on positive clinical trial results and securing adequate funding. Investors should be aware of the high risks associated with investing in clinical-stage biotechnology companies. The company shows promise but remains speculative at this stage.

Similar Stocks

Sources and Disclaimers

Data Sources:

  • Longeveron LLC Investor Relations
  • SEC Filings
  • ClinicalTrials.gov
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.

Information icon for Upturn AI Summarization accuracy disclaimer AI Summarization is directionally correct and might not be accurate.

Information icon for Upturn AI Summarization data freshness disclaimer Summarized information shown could be a few years old and not current.

Information icon warning about Upturn AI Fundamental Rating based on potentially old data Fundamental Rating based on AI could be based on old data.

Information icon warning about potential inaccuracies or hallucinations in Upturn AI-generated summaries AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Longeveron LLC

Exchange NASDAQ
Headquaters Miami, FL, United States
IPO Launch date 2021-02-12
Interim CEO & Director Mr. Than Powell
Sector Healthcare
Industry Biotechnology
Full time employees 25
Full time employees 25

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.